

MAP kinase kinase 1 inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/M733EF964540EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: M733EF964540EN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "MAP kinase kinase 1 inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in MAP kinase kinase 1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

MAP kinase kinase 1 inhibitors Understanding

MAP kinase kinase 1 inhibitors: Overview

MAPK kinases 1 and 2 (commonly known as MEK1-2) represent such proteins as they lie downstream of important drug targets for oncology, such as EGFR, RAS and RAF. MEK inhibitors hold promise for use as combination therapies for highly prevalent, genetically defined cancers owing to the critical role that the MAPK pathway plays in the growth and proliferation of many cancer types (including lung cancer, melanoma, pancreatic cancer, colorectal cancer, endometrial cancer, and ovarian cancer).

Report Highlights

The companies and academics are working to assess challenges and seek

opportunities that could influence MAP kinase kinase 1 inhibitors R&D. The therapies under development are focused on novel approaches for MAP kinase kinase 1 inhibitors.

MAP kinase kinase 1 inhibitors Emerging Drugs Chapters

This segment of the MAP kinase kinase 1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

MAP kinase kinase 1 inhibitors Emerging Drugs

Selumetinib: AstraZeneca

Selumetinib is a MEK 1/2 inhibitor used in pediatric patients to treat neurofibromatosis type 1 (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). Selumetinib is a non-ATP-competitive mitogen-activated protein kinase kinase 1 and 2 (MEK1 and MEK2) inhibitor.⁶ By selectively targeting MEK1 and MEK2, selumetinib is able to inhibit oncogenic downstream effects of the Raf-MEK-ERK signaling pathway, which is often overactive in certain types of cancer.

Mirdametinib: SpringWorks Therapeutics

Mirdametinib is an oral, allosteric, small molecule MEK inhibitor in development as a monotherapy treatment for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) and low-grade glioma (LGG), and as a combination therapy for the treatment of several subsets of biomarker-defined metastatic solid tumors. A Phase 2 investigator-initiated trial of mirdametinib in adolescents and adults with NF1-PN showed encouraging efficacy along with a generally well-tolerated safety profile. The U.S. Food and Drug Administration (FDA) and the European Commission granted Orphan Drug designation for mirdametinib for the treatment of NF1, and the FDA granted Fast Track designation for the treatment of patients \geq 2 years of age with NF1-PN that are progressing or causing significant morbidity.

Further product details are provided in the report.....

MAP kinase kinase 1 inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different MAP kinase kinase 1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on MAP kinase kinase 1 inhibitors

There are approx. 6+ key companies which are developing the MAP kinase kinase 1 inhibitors. The companies which have their MAP kinase kinase 1 inhibitors drug candidates in the most advanced stage, i.e. Phase II include, SpringWorks Therapeutics

Phases

DelveInsight's report covers around 6+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

MAP kinase kinase 1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

MAP kinase kinase 1 inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses MAP kinase kinase 1 inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MAP kinase kinase 1 inhibitors drugs.

MAP kinase kinase 1 inhibitors Report Insights

- MAP kinase kinase 1 inhibitors Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

MAP kinase kinase 1 inhibitors Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing MAP kinase kinase 1 inhibitors drugs?

How many MAP kinase kinase 1 inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of MAP kinase kinase 1 inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the MAP kinase kinase 1 inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for MAP kinase kinase 1 inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

AstraZeneca

SpringWorks Therapeutics

Array BioPharma

Novartis

Chongqing Fochon Pharmaceutical

Recursion Pharmaceuticals

CStone Pharmaceuticals

Key Products

Selumetinib

Mirdametinib

Binimetinib

Trametinib

FCN 159

REC 4881

CS 3006

Contents

Introduction

Executive Summary

MAP kinase kinase 1 inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

MAP kinase kinase 1 inhibitors – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Selumetinib: AstraZeneca

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Mirdametinib: SpringWorks Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I and I/II)

Comparative Analysis

CS 3006: CStone Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis
REC 4881: Recursion Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
MAP kinase kinase 1 inhibitors Key Companies
MAP kinase kinase 1 inhibitors Key Products
MAP kinase kinase 1 inhibitors- Unmet Needs
MAP kinase kinase 1 inhibitors- Market Drivers and Barriers
MAP kinase kinase 1 inhibitors- Future Perspectives and Conclusion
MAP kinase kinase 1 inhibitors Analyst Views
MAP kinase kinase 1 inhibitors Key Companies
Appendix

I would like to order

Product name: MAP kinase kinase 1 inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/M733EF964540EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M733EF964540EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970